Xbrane Biopharma AB (STU:7XB) EV-to-Revenue : 2.29 (As of Jun. 13, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Xbrane Biopharma AB's enterprise value is €38.01 Mil. Xbrane Biopharma AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €16.59 Mil. Therefore, Xbrane Biopharma AB's EV-to-Revenue for today is 2.29.

The historical rank and industry rank for Xbrane Biopharma AB's EV-to-Revenue or its related term are showing as below:

STU:7XB' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.14 Med: 39.85 Max: 2614.09
Current: 2.25

During the past 11 years, the highest EV-to-Revenue of Xbrane Biopharma AB was 2614.09. The lowest was 0.14. And the median was 39.85.

STU:7XB's EV-to-Revenue is ranked better than
78.72% of 1034 companies
in the Biotechnology industry
Industry Median: 7.93 vs STU:7XB: 2.25

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-13), Xbrane Biopharma AB's stock price is €0.0213. Xbrane Biopharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.06. Therefore, Xbrane Biopharma AB's PS Ratio for today is 0.33.

Xbrane Biopharma AB EV-to-Revenue Historical Data

The historical data trend for Xbrane Biopharma AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB EV-to-Revenue Chart

Xbrane Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

631.01

200.75

221.62

36.44

1.94

Xbrane Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															20.38	15.13	4.67	1.94	2.21

Competitive Comparison of Xbrane Biopharma AB's EV-to-Revenue

For the Biotechnology subindustry, Xbrane Biopharma AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xbrane Biopharma AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's EV-to-Revenue falls into.

Xbrane Biopharma AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Xbrane Biopharma AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	38.014	/	16.59
	=	2.29

Xbrane Biopharma AB's current Enterprise Value is €38.01 Mil.
Xbrane Biopharma AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €16.59 Mil.

Xbrane Biopharma AB (STU:7XB) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Xbrane Biopharma AB's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.0213	/	0.064
	=	0.33

Xbrane Biopharma AB's share price for today is €0.0213.
Xbrane Biopharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.06.

Xbrane Biopharma AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Xbrane Biopharma AB (STU:7XB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

XBRANE:Sweden 7XB:Germany

Address

Retzius vag 8, Solna, SWE, 171 65

Website

https://www.xbrane.com

Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (STU:7XB) Headlines

No Headlines